Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
29 janv. 2024 04h00 HE
|
Alvotech
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints Prolia® and Xgeva® (denosumab) are indicated...
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
29 janv. 2024 04h00 HE
|
Alvotech
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpointsProlia® and Xgeva® (denosumab) are indicated...
Alvotech birtir upplýsingar um stöðu umsókna um markaðsleyfi fyrir AVT02 og AVT04 í Bandaríkjunum
19 janv. 2024 11h30 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að úttekt eftirlitsaðila Matvæla- og lyfjaeftirlits Bandaríkjanna (FDA) á framleiðsluaðstöðu Alvotech í Reykjavík, sem hófst 10. janúar sl., sé nú lokið....
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
19 janv. 2024 11h30 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of Alvotech’s...
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
10 janv. 2024 03h30 HE
|
Alvotech
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatologyAuthorization paves...
Alvotech og STADA hljóta markaðsleyfi fyrir fyrstu líftæknilyfjahliðstæðuna við Stelara í Evrópu
10 janv. 2024 03h30 HE
|
Alvotech
Markaðsleyfi er veitt á Evrópska efnahagssvæðinu fyrir hliðstæðu við Stelara, líftæknilyf sem notað er til meðferðar við meltingar-, húð- og gigtarsjúkdómum Samkeppni um ustekinumab markaðinn í...
STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
10 janv. 2024 03h30 HE
|
Alvotech
Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within gastroenterology, dermatology, and rheumatology Authorization paves...
Niðurstaða rannsóknar á sjúklingum sýnir sömu klínísku virkni AVT06 líftæknilyfjahliðstæðu Alvotech og Eylea
03 janv. 2024 03h30 HE
|
Alvotech
Aðalendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT06 og Eylea (aflibercept) í sjúklingum með aldurstengda vota augnbotnahrörnun (AMD) ...
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
03 janv. 2024 03h30 HE
|
Alvotech
The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular...
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
11 déc. 2023 08h00 HE
|
AiViva Biopharma
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced...